Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study.
Journal: Annals of medicine
Published: September 20, 2025
Anomalous education: You can't bypass electrodiagnostic training in PM&R residency.
Journal: PM & R : the journal of injury, function, and rehabilitation
Published: September 13, 2024
Prevalence of Pathogenic Transthyretin Gene Variants in the Rocky Mountain Region.
Journal: Muscle & nerve
Published: May 20, 2024
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study
Journal: Neurology
Published: January 02, 2024
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study.
Journal: Neurology and therapy
Published: December 06, 2023
Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis.
Journal: Therapeutics and clinical risk management
Published: August 05, 2023
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: September 19, 2022
Electrodiagnostic Assessment of Motor Neuron Disease.
Journal: Neurologic clinics
Published: October 04, 2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 24, 2020
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Journal: JAMA neurology
Published: August 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Journal: The Lancet. Neurology
Published: February 24, 2020
Last Updated: 09/26/2026